Compound ID | 2884
CMTX101
Class: Antibody
| Agent Type: | Natural product; Antibody; |
| Spectrum of activity: | Gram-negative |
| Target Pathogen: | Broad-spectrum activity; developed for community acquired bacterial pneumoniae (Pseudomonas aeruginosa) |
| Description: | Immune-enabling antibody therapy; intended for infections associated with biofilm |
| Institute where first reported: | Clarametyx Biosciences, Inc. |
| Year first mentioned: | 2023 |
| Highest developmental phase: | Phase 1 (NCT06159725) |
| Development status: | Active as of 2024 |
| External links: | |
| Guide to Pharmacology: | CMTX-101 |
| Citations: |
|
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.